Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma (MRD2START)

NCT06914011 PHASE3 NOT_YET_RECRUITING

This study was a multicenter, randomized, phase 3 trial to determine whether adjuvant chemotherapy including tisleliizumab improves recurrence-free survival compared to follow-up alone without chemotherapy in patients with curatively resected esophageal squamous cell carcinoma.

Details

Lead sponsor	Asan Medical Center
Phase	PHASE3
Status	NOT_YET_RECRUITING
Enrolment	172
Start date	Tue Jan 06 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue May 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Esophageal Cancer

Interventions

• Tislelizumab